Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIT2KFUVR)
  Drug Name Interferon alfa-2a, Recombinant Drug Info Asparaginase Erwinia chrysanthemi Drug Info
  Drug Type Interferons Protein/peptide
  Therapeutic Class Interferons Antineoplastics

 Mechanism of Interferon alfa-2a, Recombinant-Asparaginase Erwinia chrysanthemi Interaction (Severity Level: Moderate)
     Increased risk of hepatotoxicity Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Interferon alfa-2a, Recombinant Asparaginase Erwinia chrysanthemi
      Mechanism Hepatotoxicity Hepatotoxicity
      Key Mechanism Factor 1
Factor Name Hepatotoxicity
Factor Description Combination of drugs that can induce hepatotoxicity may increase the risk of liver injury. Symptoms vary depending on the level of exposure and the total extent of liver damage, and may cause few symptoms if the damage is mild, and eventually lead to liver failure in patients with severe damage.
      Mechanism Description
  • Increased risk of hepatotoxicity by the combination of Interferon alfa-2a, Recombinant and Asparaginase Erwinia chrysanthemi 

Recommended Action
      Management The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.

References
1 Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
2 Cerner Multum, Inc. "Australian Product Information.".
3 Product Information. Oncaspar (pegaspargase). Rhone-Poulenc Rorer, Collegeville, PA.